Drug Trial Radar · NCT07596849
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease.
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
230
Planned (sponsor's estimate)
Start
Jun 10, 2026
Primary completion
Jun 2028
Study completion May 2030
Sponsor
- Lead sponsor
- argenxargenx (ARGX)
- Sponsor type
- Industry
- First posted
- May 19, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to look at how efgartigimod affects thyroid function in adults with Graves' Disease (GD). The study will also check whether efgartigimod is safe and well tolerated. It will look at how efgartigimod is distributed and eliminated in the body, how it changes antibody levels, and how the immune system responds to it. The study consists of a part A double-blinded treatment period, a part B treatment/observation period and a part C open-label treatment/observation period. During the part A and part B treatment periods, participants will receive efgartigimod PH20 SC via Prefilled Syringe (PFS) or placebo. During the part C open-label treatment period, participants will receive efgartigimod PH20 SC PFS. Participation in the different parts of the study will depend on the participant's response to treatment. The total study duration for participants ranges from 63 to 135 weeks, depending on the response to treatment. More information can be found here: https://clinicaltrials.argenx.com/vitalithy
Conditions
- Graves Disease
Interventions
efgartigimod PH20 SCBiological
Subcutaneous injection of Efgartigimod PH20 Via Prefilled Syringe (PFS)
Placebo PH20 SCOther
Subcutaneous injection of placebo PH20 via Prefilled Syringe (PFS)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants who are euthyroid (fT3, fT4, and TSH within normal ranges) off ATDs at week 24 in part ATime frame: up to 24 weeks (part A)
Locations
51 sites in 14 countries. Site status is shown where the registry gives one.
Universitair Ziekenhuis Gent
Ghent, Belgium · Recruiting
AZORG Ziekenhuis
Aalst, Oost-Vlass, Belgium · Recruiting
Medical Center Tonus - 2013 OOD
Pazardzhik, Bulgaria · Recruiting
DCC Pulmed
Plovdiv, Bulgaria · Recruiting
Multiprofile Hospital for Active Treatment Hadzhi Dimitar OOD
Sliven, Bulgaria · Recruiting
Medical Center Kalimat
Sofia, Bulgaria · Recruiting
Diagnostic Consultative Center Ekvita OOD
Varna, Bulgaria · Recruiting
MC Klinika Nova
Varna, Bulgaria · Recruiting
Multi-Profile District Hospital for Active Treatment Dr. Stefan Cherkezov
Veliko Tarnovo, Bulgaria · Recruiting
TLC Diabetes and Endocrinology Clinic
Surrey, Canada · Recruiting
Endocrinologie Oasis
Montreal, Quebec, Canada · Recruiting
Nordsjaellands Hospital - Hillerod
Hillerød, Capital Region, Denmark · Recruiting
High Technology Hospital Medcenter LLC
Batumi, Georgia · Recruiting
First Medical Clinic Ltd
Tbilisi, Georgia · Recruiting
LTD MediClub Georgia
Tbilisi, Georgia · Recruiting
Institut fuer Praeventive Medizin & Klinische Forschung
Magdeburg, Germany · Recruiting
Evangelismos Hospital
Athens, Greece · Recruiting
Athens Medical Center
Athens, Greece · Recruiting
AOU Ospedali Riuniti di Ancona Umberto I-G.M. Lancisi-G. Salesi
Ancona, Italy · Recruiting
Aso Iizuka Hospital
Iizuka, Japan · Recruiting
Nippon Medical School Musashikosugi Hospital
Kawasaki, Japan · Recruiting
Hospital of University of Occupational and Environmental Health
Kitakyushu, Japan · Recruiting
National Hospital Organization Kyoto Medical Center
Kyoto, Japan · Recruiting
Nagasaki University Hospital
Nagasaki, Japan · Recruiting
Ito Hospital
Shibuya City, Japan · Recruiting
SHOWA Medical University Northern Yokohama Hospital
Yokohama, Japan · Recruiting
Tottori University Hospital
Yonago, Japan · Recruiting
Okayama University Hospital
Okayama, Okayama-ken, Japan · Recruiting
Juntendo University Hospital
Bunkyō-Ku, Tokyo, Japan · Recruiting
Toho University Omori Medical Center
Ōta-ku, Tokyo, Japan · Recruiting
LTD M & M Centers
Adazi, Latvia · Recruiting
Veselibas centrs 4
Riga, Latvia · Recruiting
Klaipeda's University Hospital
Klaipėda, Lithuania · Recruiting
Hospital of Lithuanian University of Health Sciences Kaunas
Kaunas, Kauno, Lithuania · Recruiting
Centrum Medyczne INTERCOR Sp. z o.o.
Bydgoszcz, Poland · Recruiting
DIABET Centrum Medyczne s.c.
Chrzanów, Poland · Recruiting
ETG Lublin
Lublin, Poland · Recruiting
Reumed Sp Z O.O.
Lublin, Poland · Recruiting
NZOZ GynCentrum - Oddzial Warszawa
Warsaw, Poland · Recruiting
ETG JustMed
Warsaw, Poland · Recruiting
Showing 40 of 51 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.